Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group

Am J Cardiol. 1998 Apr 1;81(7):912-7. doi: 10.1016/s0002-9149(98)00010-1.

Abstract

The hypolipidemic action of fibrates has recently been shown to involve the activation of peroxisome proliferator activated receptors establishing a molecular mechanism for this class of drugs. Increasing clinical trial evidence supports the efficacy of fibrates in the treatment of dyslipoproteinemias, particularly in patients with hypertriglyceridemia and low high-density lipoproteins.

Publication types

  • Consensus Development Conference
  • Review

MeSH terms

  • Animals
  • Cholesterol, LDL / blood
  • Clofibrate / therapeutic use
  • Coronary Disease / drug therapy*
  • Coronary Disease / epidemiology
  • Female
  • Gemfibrozil / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Hyperlipoproteinemias / drug therapy*
  • Hyperlipoproteinemias / epidemiology
  • Hypolipidemic Agents / therapeutic use*
  • Male
  • Risk Factors

Substances

  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Hypolipidemic Agents
  • Clofibrate
  • Gemfibrozil